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There are numerous benefits to the research community from data sharing, and yet the open sharing of participant
level data is not without potential pitfalls. In addition to the scientific community, the interests of study participants
who volunteered their data must be considered, along with the interests of study investigators who expend a
substantial amount of effort into the design, conduct, and analytical plans for the study. The National Heart, Lung,
and Blood Institute (NHLBI) has developed a data-sharing protocol focused on balancing the interests of study
participants, study investigators, and the research community with independent oversight by the NHLBI IRB. The data
repository presently includes individual level data on more than 560,000 participants from 100 Institute-supported
clinical trials and observational studies.
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There are many potential uses of existing data: meta-
analyses, applications of innovative statistical methods,
replication, novel new analyses, cross-study comparisons,
and sample size estimation for new studies. The benefits
to the research community of data sharing are consistently
heralded in the literature [1-6], and yet the open sharing
of participant level data is not without potential pitfalls.
First and foremost, the interests of study participants who
volunteered their data must be considered along with the
interests of study investigators. Participants volunteer
their time and data for a variety of reasons [7,8] and
maintenance of participant privacy is a primary concern
[9,10]. Study investigators expend a substantial amount
of effort into the design, conduct, and analytical plans
for studies, and are rightfully entitled to a protected
period of time with the data. Additionally, investigators that
collected the data are in the best position to understand the
nuances associated with the study and concerns over
poorly designed secondary analyses or the motives of those
requesting access to data have been expressed [11-13].
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Sharing this clinical data in a manner that balances the
interests of study participants, study investigators, and the
research community is the subject of this commentary.Discussion
A brief history of the NHLBI data repository
A formal data sharing policy, applicable to Institute-
supported contract studies, was first established by the
Institute in 1989 under then Director Claude L’Enfant.
This first data-sharing policy timed release of data to
within 3 years of ‘major publications’ and described
generally the data that were to be removed from a study
dataset prior to release. Although a formal data-sharing
policy for contract-supported studies had been established,
the availability of these datasets was not well-known, there
was a lack of guidance on what process should be used to
distribute datasets, and it was unclear as to what data
should be made available. A revised policy, incorporating
specific data release timelines, guidelines for data
submission, and the data request process was developed
in 1999. Since all of the data for the data repository were
derived from human subjects in both ongoing and
closed studies, the policy was submitted to the NHLBI
Institutional Review Board (IRB) as a formal protocol
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nually review the activities of the data repository.
The current data-sharing policy
The data-sharing protocol has evolved over time, ex-
panding to include grant-supported studies as well as
contract-supported studies. Clarification of the common
rule regarding local IRB review for secondary analysis of
existing data provided additional guidance on how re-
quests for data should be reviewed, and studies depositing
data into the repository are now required to certify that
the data can be shared with outside investigators.
The data repository protocol can be divided into three
aspects: rules for when data will be released and what data
to include, rules for submitting data to the repository, and
rules governing how data will be shared.
Data and timelines for release
The data released to the general research community
through the data repository consist of all data collected dur-
ing the conduct of the study including: baseline, interim
visit(s), laboratory measurements, and outcome data. To
minimize re-identification risks and provide reasonable
protection for participant privacy, the de-identification pro-
cedures for data included in the repository generally follow
the HIPAA privacy act [14], these include, but are not lim-
ited to: removal of all obvious identifiers (name, address,
social security number, date of birth), removal of all dates
and replacement with time intervals (that is, time since
randomization or time since enrollment), and geography is
generally removed. Other redactions are also encouraged
such as top/bottom coding of height and weight, categoriz-
ing traits such as race/ethnicity, marital status, education,
income, and so on, to reduce any re-identification risk. Sen-
sitive items such as sexual behaviors or illicit drug use may
be removed from the data when these data elements are
not part of the primary focus of the study; therefore, as op-
posed to ‘rules’ for de-identification, the redaction process
is more aptly described as following ‘guidelines’, in which
considerable judgment on the part of the study is needed to
maintain scientific utility and also protection of participant
privacy. The goal is to minimize re-identification risk while
maximizing secondary use of the redacted datasets. Over-
redaction can result in a dataset with low utility.
Datasets are released following a standard timeline.
Study investigators are given a protected period of time
(2 years) to prepare key manuscripts from the study. In
this manner the data are made available to the general
research community within a reasonable time frame and
provides the investigators who collected the data time to
publish study results.
Data collection for clinical trials is generally prede-
fined with specific starting and ending dates; however,
observational studies may collect data over many years.Therefore, the protocol defines data release in a slightly
different manner depending on the study type. Specifically,
the protocol states that data from observational studies
are made available: (1) 3 years after the last participant
visit for a clinic exam cycle or close out date for event
ascertainment; or (2) 2 years after the exam or surveillance
data are made available for within study use. Ongoing
observational studies will therefore tend to have periodic
updates to their data. Data from clinical trials are made
available 2 years after publication of the primary outcome
paper or 3 years after the end of clinical activity.
It is important to note that most large clinical trials
and observational studies have active publications/pres-
entation committees that are open to collaborations with
outside investigators. These studies are essentially open
to immediate data-sharing using study-specific internal
policies.
Submitting data to the repository
Release of data through the data repository is required
for Institute-supported contract studies and may also
be required for certain large grants or cooperative
agreements. The inclusion of grant-supported studies
was introduced in 2005 and applies to studies
reviewed and initiated after October 1, 2005. In brief,
grant-supported studies with direct costs equal to or
greater than $500K in any 1 year and identified as
being of high programmatic interest, along with co-
operative agreements with 500 or more participants
are required to submit data to the data repository as
part of the grant award.
All data submitted to the data repository must be consist-
ent with the informed consent. Participants explicitly
requesting that their data not be shared must be removed
from all repository datasets and any other consent restric-
tions must be noted. For example, the informed consent for
the Hemochromatosis and Iron Overload Screening Study
(HEIRS) indicated that participants’ data would only be
used for ‘iron-related and hereditary hemochromatosis
studies’. Therefore, any requests for HEIRS study data must
have an iron-related focus.
Following on the database of Genotypes and Pheno-
types (dbGaP) experience, institutions submitting data to
the data repository are required to certify that the data
can be shared. In brief, the certification affirms to the
NHLBI that the informed consent explicitly permits
sharing data with other investigators, or the depositing
Institution’s IRB has approved the sharing of the partici-
pants’ data.
Accessing data in the repository
Applications for study datasets in the Data Repository
are done online at www.biolincc.nhlbi.nih.gov. The web-
site is maintained by the NHLBI Biologic Specimen and
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(BioLINCC) program. The online application for study
datasets include: (1) a description of the research pro-
ject; (2) local IRB review or institutional certification of
exemption from IRB review; and (3) agreeing to the
terms and conditions of a data use agreement (termed a
Research Materials Distribution Agreement (RMDA)
since both biospecimens and data can be obtained from
the NHLBI repositories). Terms of the RMDA include
provisions limiting use of the data to 3 years, prohibits
transfer of the data to another party, requires appropri-
ate computer security measures, and specifies the
acknowledgment to be used in manuscripts. Both the
investigator and the Institution are required to sign and
agree to the terms of the RMDA. Applicants are not
subject to a scientific review, but instead an administra-
tive review is conducted to ensure the project is within
the spirit and intent of the data agreement. Likewise,
there is no requirement for screening manuscripts prior
to submission to a journal. The absence of a scientific
review or pre-submission review of manuscripts avoids
any perception of blocking access or controlling re-
search; however, this does allow for the possibility of
misleading or incorrect analyses to be published. The
possibility of intentionally misleading analyses is miti-
gated to some degree through the open nature of the re-
pository in that replication is possible with the identical
dataset. Avoiding unintentionally incorrect analyses is
far more difficult and is largely only correctable post
publication.
A summary of the clinical data and biospecimen resources
available are provided in Additional file 1: Table S1.Conclusion
A collaborative approach, utilizing the experience and
expertise of study investigators, is the most productive
method of data-sharing for ensuring high quality manu-
scripts. The NHLBI data repository fulfills the niche of
providing opportunities for secondary analysis of existing
data when collaborations are either unfeasible, or not de-
sired. Participant data are released, after study investiga-
tors have had a 2-year protected period of time, in a
manner consistent with the informed consent, and is
generally redacted to meet or exceed HIPAA require-
ments to maintain participant privacy.
The NHLBI has made a commitment to the sharing
of research resources to the widest possible audience
to maximize the value of Institute-supported studies.
Through a website portal, the Institute financially sup-
ports the infrastructure to efficiently process, commu-
nicate information, and distribute to the research
community data from more 560,000 study participants
and 4.6 million biological samples.Additional file
Additional file 1: Table S1. Observational studies, clinical trials, and
transfusion medicine studies with data and/or samples in the NHLBI data
and biospecimen repositories. Study acronym and number of participants
are in parentheses. Bolded studies have samples in the biorepository and
the footnotes indicate stored biospecimen types.
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